#psychedelictherapy — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #psychedelictherapy, aggregated by home.social.
-
DATE: August 10, 2026 at 09:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: A fast-acting psychedelic shows promise for postpartum depression
URL: https://www.psypost.org/a-fast-acting-psychedelic-shows-promise-for-postpartum-depression/
A single day of treatment with an inhaled psychedelic compound called mebufotenin helped relieve symptoms of postpartum depression in a small trial of new mothers. Within two hours of receiving the therapy, patients experienced a near-total reduction in depressive symptoms that lasted for the weeklong duration of the study. The research was published in The Journal of Clinical Psychiatry.
Postpartum depression is a severe mood disorder affecting women after giving birth. Symptoms often include extreme sadness, anxiety, changes in sleeping and eating habits, and difficulty bonding with the newborn. The condition affects up to one in five mothers globally. If left untreated, it can cause long-lasting harm to the psychological well-being of the mother and the cognitive development of the child.
Standard antidepressant pills, such as selective serotonin reuptake inhibitors, often take four to six weeks to begin working. They can also cause persistent side effects like weight gain, nausea, and sexual dysfunction. The only medication specifically approved by the United States Food and Drug Administration for postpartum depression is zuranolone. This oral medication works faster than standard antidepressants but still requires a fourteen-day daily regimen and comes with warnings about drowsiness.
Medical researchers are exploring psychoactive compounds as potential alternatives for rapid relief. Mebufotenin, also known as 5-MeO-DMT, is a potent psychedelic molecule that acts directly on the brain’s serotonin receptors. Serotonin is a chemical messenger that helps regulate mood, sleep, and digestion. In previous early-stage trials, inhaling a synthetic version of mebufotenin called GH001 produced extremely fast antidepressant effects in people with treatment-resistant depression.
Lead authors Martin Johnson of St. Pancras Clinical Research and Kristina M. Deligiannidis of the Feinstein Institutes for Medical Research wanted to test if this formulation could safely help mothers experiencing severe postpartum depression. They organized a clinical trial to evaluate the compound’s safety, side effects, and impact on maternal functioning. The trial was funded by GH Research, the company developing the drug.
The researchers enrolled ten women between the ages of eighteen and forty-five. All the participants had a confirmed diagnosis of major depressive disorder that began shortly before or after giving birth. The mothers had to be at least four weeks postpartum to participate. To qualify, the women had to score at least twenty-eight on a standard questionnaire used to measure depression severity, which indicates moderate to severe depression.
On the day of the treatment, the researchers administered the drug using a specialized vaporization system. The patients inhaled the medication from a collected balloon. The dosing was individualized for each patient based on how they responded to the drug.
Participants received an initial six-milligram dose of the compound. If they tolerated it well but did not achieve an intense psychoactive peak experience, the medical team gave them a higher twelve-milligram dose one hour later. A third dose of eighteen milligrams was given an hour after that if the intense psychedelic effects were still not reached.
The researchers used a specialized scale to determine if a patient had reached a peak experience. This assessment measured the overall intensity of the psychoactive effects, any feelings of a loss of control, and how profound the experience felt to the patient. Once a patient reached a high score on this assessment, the medical team stopped administering further doses.
The researchers monitored the patients’ vital signs, psychiatric symptoms, and overall comfort during the treatment day. Because mebufotenin acts very quickly in the brain, the psychedelic effects lasted an average of about twenty to twenty-five minutes per dose. The trial required patients to have a trusted caregiver at home to look after their infant while they participated.
The primary goal was to see how the patients’ depression scores changed from the beginning of the study to day eight. The researchers also measured depression scores two hours after the final dose and on day two. Four of the women were lactating, so the team tested their breast milk to see how quickly the drug was eliminated from their bodies.
The results of this small study showed immediate reductions in depression scores. Two hours after the final dose, all ten patients saw a reduction in symptoms of at least fifty percent. By day eight, the average depression score dropped by about ninety-six percent. Every single participant reached full remission, meaning they no longer met the clinical criteria for depression.
The patients also reported major improvements in maternal functioning. By day eight, their scores on a questionnaire assessing psychological well-being, self-care, and mother-child interaction increased by about fifty-six percent. These gains were observed across almost all areas of maternal behavior measured by the researchers.
The inhaled medication was well tolerated by the participants. No serious adverse events occurred. The most common side effect was a mild to moderate headache, which affected half of the women. Unlike some other depression medications, the treatment did not cause lingering sedation, allowing all patients to go home on the same day.
The breast milk analysis for the lactating mothers showed that the drug and its byproducts were eliminated from their systems very quickly. The chemical traces peaked around one hour after the final dose and fell below detectable levels by about ten hours. This suggests that mothers might only need to pause breastfeeding for a brief window on the day of treatment.
As an open-label trial, both the patients and the researchers knew that the active drug was being administered. There was no placebo group for comparison. This design makes it impossible to rule out the placebo effect, where a patient’s expectation of getting better influences their actual symptoms.
The sample size of ten patients is quite small, and the group lacked demographic diversity. Nine of the ten participants were white. Almost none of the patients were taking other psychiatric medications during the trial. The results might not represent how the broader, more diverse population of mothers with postpartum depression would respond to the drug.
The study only tracked the women for one week after the treatment. This short timeframe leaves unanswered questions about how long the antidepressant effects might last. Future studies will need to follow patients over several months to see if the depression returns or if additional doses are required.
Later stages of research will involve larger groups of patients who are randomly assigned to receive either the active drug or a placebo. Those trials will be necessary to confirm the safety profile and to verify that the drug itself is directly responsible for the rapid relief of symptoms.
The study, “Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” was authored by Martin Johnson, Pau Aceves Baldo, Emilio Arbe, Brian Brennan, Sem E. Cohen, Kelly Doolin, William Gann, David Gregory, Sarah Keady, Katerina Kriger, Rachael MacIsaac, Stuart Ratcliffe, David R. Rubinow, Claus Bo Svendsen, Theis H. Terwey, Dan Tully, Velichka Valcheva, Jasper B. Zantvoord, and Kristina M. Deligiannidis.
URL: https://www.psypost.org/a-fast-acting-psychedelic-shows-promise-for-postpartum-depression/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PostpartumDepression #Mebufotenin #GH001 #PsychedelicTherapy #RapidAntidepressant #MaternalHealth #PostpartumRecovery #DepressionTreatment #BreastfeedingSafety #ClinicalTrial
-
DATE: August 10, 2026 at 09:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: A fast-acting psychedelic shows promise for postpartum depression
URL: https://www.psypost.org/a-fast-acting-psychedelic-shows-promise-for-postpartum-depression/
A single day of treatment with an inhaled psychedelic compound called mebufotenin helped relieve symptoms of postpartum depression in a small trial of new mothers. Within two hours of receiving the therapy, patients experienced a near-total reduction in depressive symptoms that lasted for the weeklong duration of the study. The research was published in The Journal of Clinical Psychiatry.
Postpartum depression is a severe mood disorder affecting women after giving birth. Symptoms often include extreme sadness, anxiety, changes in sleeping and eating habits, and difficulty bonding with the newborn. The condition affects up to one in five mothers globally. If left untreated, it can cause long-lasting harm to the psychological well-being of the mother and the cognitive development of the child.
Standard antidepressant pills, such as selective serotonin reuptake inhibitors, often take four to six weeks to begin working. They can also cause persistent side effects like weight gain, nausea, and sexual dysfunction. The only medication specifically approved by the United States Food and Drug Administration for postpartum depression is zuranolone. This oral medication works faster than standard antidepressants but still requires a fourteen-day daily regimen and comes with warnings about drowsiness.
Medical researchers are exploring psychoactive compounds as potential alternatives for rapid relief. Mebufotenin, also known as 5-MeO-DMT, is a potent psychedelic molecule that acts directly on the brain’s serotonin receptors. Serotonin is a chemical messenger that helps regulate mood, sleep, and digestion. In previous early-stage trials, inhaling a synthetic version of mebufotenin called GH001 produced extremely fast antidepressant effects in people with treatment-resistant depression.
Lead authors Martin Johnson of St. Pancras Clinical Research and Kristina M. Deligiannidis of the Feinstein Institutes for Medical Research wanted to test if this formulation could safely help mothers experiencing severe postpartum depression. They organized a clinical trial to evaluate the compound’s safety, side effects, and impact on maternal functioning. The trial was funded by GH Research, the company developing the drug.
The researchers enrolled ten women between the ages of eighteen and forty-five. All the participants had a confirmed diagnosis of major depressive disorder that began shortly before or after giving birth. The mothers had to be at least four weeks postpartum to participate. To qualify, the women had to score at least twenty-eight on a standard questionnaire used to measure depression severity, which indicates moderate to severe depression.
On the day of the treatment, the researchers administered the drug using a specialized vaporization system. The patients inhaled the medication from a collected balloon. The dosing was individualized for each patient based on how they responded to the drug.
Participants received an initial six-milligram dose of the compound. If they tolerated it well but did not achieve an intense psychoactive peak experience, the medical team gave them a higher twelve-milligram dose one hour later. A third dose of eighteen milligrams was given an hour after that if the intense psychedelic effects were still not reached.
The researchers used a specialized scale to determine if a patient had reached a peak experience. This assessment measured the overall intensity of the psychoactive effects, any feelings of a loss of control, and how profound the experience felt to the patient. Once a patient reached a high score on this assessment, the medical team stopped administering further doses.
The researchers monitored the patients’ vital signs, psychiatric symptoms, and overall comfort during the treatment day. Because mebufotenin acts very quickly in the brain, the psychedelic effects lasted an average of about twenty to twenty-five minutes per dose. The trial required patients to have a trusted caregiver at home to look after their infant while they participated.
The primary goal was to see how the patients’ depression scores changed from the beginning of the study to day eight. The researchers also measured depression scores two hours after the final dose and on day two. Four of the women were lactating, so the team tested their breast milk to see how quickly the drug was eliminated from their bodies.
The results of this small study showed immediate reductions in depression scores. Two hours after the final dose, all ten patients saw a reduction in symptoms of at least fifty percent. By day eight, the average depression score dropped by about ninety-six percent. Every single participant reached full remission, meaning they no longer met the clinical criteria for depression.
The patients also reported major improvements in maternal functioning. By day eight, their scores on a questionnaire assessing psychological well-being, self-care, and mother-child interaction increased by about fifty-six percent. These gains were observed across almost all areas of maternal behavior measured by the researchers.
The inhaled medication was well tolerated by the participants. No serious adverse events occurred. The most common side effect was a mild to moderate headache, which affected half of the women. Unlike some other depression medications, the treatment did not cause lingering sedation, allowing all patients to go home on the same day.
The breast milk analysis for the lactating mothers showed that the drug and its byproducts were eliminated from their systems very quickly. The chemical traces peaked around one hour after the final dose and fell below detectable levels by about ten hours. This suggests that mothers might only need to pause breastfeeding for a brief window on the day of treatment.
As an open-label trial, both the patients and the researchers knew that the active drug was being administered. There was no placebo group for comparison. This design makes it impossible to rule out the placebo effect, where a patient’s expectation of getting better influences their actual symptoms.
The sample size of ten patients is quite small, and the group lacked demographic diversity. Nine of the ten participants were white. Almost none of the patients were taking other psychiatric medications during the trial. The results might not represent how the broader, more diverse population of mothers with postpartum depression would respond to the drug.
The study only tracked the women for one week after the treatment. This short timeframe leaves unanswered questions about how long the antidepressant effects might last. Future studies will need to follow patients over several months to see if the depression returns or if additional doses are required.
Later stages of research will involve larger groups of patients who are randomly assigned to receive either the active drug or a placebo. Those trials will be necessary to confirm the safety profile and to verify that the drug itself is directly responsible for the rapid relief of symptoms.
The study, “Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” was authored by Martin Johnson, Pau Aceves Baldo, Emilio Arbe, Brian Brennan, Sem E. Cohen, Kelly Doolin, William Gann, David Gregory, Sarah Keady, Katerina Kriger, Rachael MacIsaac, Stuart Ratcliffe, David R. Rubinow, Claus Bo Svendsen, Theis H. Terwey, Dan Tully, Velichka Valcheva, Jasper B. Zantvoord, and Kristina M. Deligiannidis.
URL: https://www.psypost.org/a-fast-acting-psychedelic-shows-promise-for-postpartum-depression/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PostpartumDepression #Mebufotenin #GH001 #PsychedelicTherapy #RapidAntidepressant #MaternalHealth #PostpartumRecovery #DepressionTreatment #BreastfeedingSafety #ClinicalTrial
-
DATE: August 9, 2026 at 11:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin combined with talk therapy shows potential for treating anorexia nervosa
A recent pilot study suggests that psilocybin, the active compound in “magic mushrooms,” provides evidence of safety and potential psychological benefits for adult women with anorexia nervosa when paired with extensive talk therapy. The findings indicate that this combined approach might help reduce eating disorder symptoms and increase a patient’s internal motivation to recover. The research, which offers a possible new avenue for a condition that is notoriously difficult to treat, was published in The British Journal of Psychiatry.
Anorexia nervosa is a psychiatric condition characterized by a severe restriction of food intake, an extreme fear of gaining weight, and a distorted perception of body shape. It has one of the highest mortality rates among all psychiatric conditions and frequently becomes intertwined with a person’s sense of identity. This integration into a person’s identity often makes the disorder highly resistant to conventional psychological interventions. Up to 30 percent of diagnosed individuals develop a chronic version of the illness that does not respond to standard care.
Because existing treatments often fail, scientists have started exploring alternative pharmacological approaches, including psychedelic substances. Psilocybin is a naturally occurring compound that interacts with serotonin receptors in the brain to produce altered states of consciousness. Recent systematic reviews of the literature by Francesco Bevione and colleagues highlighted that early, small-scale trials and case studies have provided evidence that psilocybin is generally safe for people with eating disorders.
Animal models have also provided insights into how this drug might operate in the brain. Research led by Claire J. Foldi demonstrated that psilocybin helped female rats subjected to an anorexia model maintain their body weight and improve their cognitive flexibility, which is the ability to adapt to new rules and environments.
This animal research indicated that the drug alters the expression of specific serotonin receptors in the brain, particularly the 5-HT1A and 5-HT2A receptors. However, related studies on mice suggest that psilocybin’s physiological effects, such as its impact on immune system inflammation, depend heavily on an animal’s physical state and environment.
To build on this preliminary data, a team of researchers from the Centre for Psychedelic Research at Imperial College London designed a pilot study to test the intervention in humans. The research was led by Hannah M. Douglass alongside Robin L. Carhart-Harris. They aimed to assess the safety, feasibility, and potential psychological benefits of psilocybin therapy in a group of adult women who had not responded to traditional anorexia treatments.
The researchers recruited 21 female participants between the ages of 23 and 52 who had a primary diagnosis of anorexia nervosa for at least three years. On average, the participants were 32 years old, had lived with the disorder for about 11 years, and had an average Body Mass Index (BMI) of 16.4. A healthy BMI is generally considered to be 18.5 or higher. The participants had not found long-term success with previous treatments.
The study utilized a single-blind, within-individual design, meaning there was no separate control group that received a placebo for the entire study. Over a six-week period, all 21 women attended three dosing sessions. They received a 1-milligram dose of psilocybin first, which was intended to be so low that it acted as a placebo. This was followed by two 25-milligram doses, spaced two weeks apart. Participants knew they were receiving psilocybin but did not know the dosage order.
Each dosing session took place in a supportive environment and was flanked by extensive preparation and integration talk therapy. Ten of the participants were required to withdraw from antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), to prevent these drugs from blunting the psychedelic experience. The researchers monitored the participants’ safety, physical health, and psychological symptoms at multiple time points up to a year after the final session.
To measure eating disorder severity, the researchers primarily used the Eating Disorder Examination (EDE) interview, which involves a clinician assessing the patient’s symptoms. The participants had an average baseline EDE score of 3.2. The research team also used the Readiness and Motivation Questionnaire (RMQ) to track the participants’ self-reported motivation to recover.
The administration of psilocybin was well tolerated by the participants. All 21 women experienced at least one adverse event, but most were mild to moderate in severity. The most common side effects were transient headaches, reported by about 37 percent of participants, and nausea, reported by 25 percent. The study did not track BMI for the full year, but during the initial six weeks, the researchers noted no meaningful change in the participants’ body weight.
The clinician-administered assessments indicated that eating disorder symptoms decreased over time. The average global EDE score dropped by approximately 1.08 points by the final six-week visit. This reduction represents a massive relative drop from the 3.2 baseline score, yielding a large effect size. These improvements were generally sustained, with a 0.98-point reduction maintained at the six-month follow-up. Nearly all participants showed some level of improvement two weeks after the final session.
By the three-month mark, almost half of the participants had achieved symptom scores that fell within the range of a normal community population without an eating disorder. The researchers noted that individuals with a higher severity of symptoms at the start of the study tended to experience greater overall reductions in their scores. When analyzing the data, the scientists controlled for the potential impact of antidepressant withdrawal, finding that this variable did not alter the main outcomes.
The participants also self-reported changes in their mindset. The participants’ precontemplation scores on the RMQ decreased, indicating that their motivation to recover increased after the first 25-milligram dose. This shift toward wanting to change was sustained across the 12-month follow-up period. When comparing symptom reduction between the different dosage days, the differences were not statistically significant, indicating that the overall treatment package contributed to the psychological shifts rather than one specific dose.
Douglass, who led the study while completing her PhD at Imperial College London, reflected on the clinical outcomes. “This study delivered a brief program of psilocybin dosing and therapeutic support over a six-week period,” Douglass said. “Our results in individuals living with anorexia nervosa are encouraging, especially given that these participants had found previous treatments unsuccessful in maintaining their remission. However, further research is needed to assess how these findings might apply to a broader, more diverse population.”
The trial’s retention rate was 95.2 percent, with only one participant choosing to withdraw after the second dose due to the emotional and time commitments. Professor Robin Carhart-Harris, the senior author and trial designer, highlighted this particular success.
“This was a pioneering trial with promising results that justify larger and more rigorous studies,” Carhart-Harris said in a news release. “In particular, the retention rate was excellent, something that is often a real challenge in anorexia nervosa treatment. This was despite the considerable commitment required from participants involving day-long dosing sessions and several sessions of psychotherapy.”
The therapeutic context was an essential element of the intervention. Jennifer Danby, the lead therapist on the trial, noted how the psychedelic experience appeared to open new psychological doors for the patients.
“Having worked in the field of eating disorders for over 15 years it was encouraging to see that the trial, albeit with a very small cohort, provided an opportunity for individuals living with anorexia nervosa to approach treatment from a different angle,” Danby said. “Anorexia often serves as a protective mechanism for people and we saw participants be able to explore their relationship with the illness and gain some new perspectives. By laying fertile ground for change, even minor adjustments can lead to promising change longer term.”
David Erritzoe, another key researcher on the team, cautioned against treating the drug as a standalone cure. “The findings bear out further research, but it’s important to note that this was a particular dosing model carefully designed to support vulnerable participants with extensive psychological therapy alongside the psychedelic treatment,” Erritzoe said. “To be effective and safe, psychedelic treatments for individuals with complex mental health presentations, such as anorexia nervosa, should be given by trained clinicians in a supportive environment.”
The absence of a separate, drug-free control group makes it impossible to definitively attribute the observed psychological improvements to the psilocybin itself. Participants received roughly 50 hours of therapeutic contact during the six-week study. This intensive psychological support, combined with the natural passage of time, may have driven the reductions in eating disorder symptoms. A randomized controlled trial is necessary to separate the chemical effects of the drug from the benefits of the accompanying psychotherapy.
The study’s participants were relatively homogenous. The majority were highly educated white women. This demographic profile does not represent the full spectrum of individuals who suffer from eating disorders. The strict eligibility requirements also resulted in a sample of people who might have had more stable home environments or greater cognitive reserves, which can facilitate better therapeutic engagement. As a result, these findings cannot be readily generalized to a broader or more diverse population.
There was also a high degree of variation in how well the participants maintained their symptom improvements over the long term. Some individuals experienced a return of their eating disorder thoughts and behaviors during the one-year follow-up period. This variation indicates that psilocybin therapy might not induce permanent shifts for everyone and that post-study life events play a major role in long-term recovery.
During the follow-up period, one participant attempted suicide on two occasions. The study doctors and an independent safety board assessed these events and concluded they were unlikely to be related to the psilocybin intervention, given that they occurred seven and nine months after the final dosing session. These events highlight the elevated baseline risk of suicidality in populations with severe anorexia nervosa and the absolute necessity of rigorous clinical monitoring in psychiatric research.
The study, “Psilocybin therapy for adult females with anorexia nervosa: pilot study,” was authored by Hannah M. Douglass, Meg J. Spriggs, Kate Godfrey, Jennifer L. Danby, Frederico J. C. de Magalhaes, Lauren Macdonald, Kirsty L. Alderton, Stephanie Archer, Kirran Ahmad, Jonny Martell, Jennifer T. Frias, Gabriela Sawicka, Tim Read, Allan Blemings, Adele Lafrance, Dasha Nicholls, David Erritzoe, Rebecca J. Park, David J. Nutt, and Robin L. Carhart-Harris.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinForAnorexia #PsychedelicTherapy #EatingDisorderRecovery #AnorexiaNervosaTreatment #MentalHealthResearch #ImperialCollegePsychedelics # RMQ #EDEassessment #CompassionateCare #PsychotherapyPlusMedicine
-
DATE: August 9, 2026 at 11:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin combined with talk therapy shows potential for treating anorexia nervosa
A recent pilot study suggests that psilocybin, the active compound in “magic mushrooms,” provides evidence of safety and potential psychological benefits for adult women with anorexia nervosa when paired with extensive talk therapy. The findings indicate that this combined approach might help reduce eating disorder symptoms and increase a patient’s internal motivation to recover. The research, which offers a possible new avenue for a condition that is notoriously difficult to treat, was published in The British Journal of Psychiatry.
Anorexia nervosa is a psychiatric condition characterized by a severe restriction of food intake, an extreme fear of gaining weight, and a distorted perception of body shape. It has one of the highest mortality rates among all psychiatric conditions and frequently becomes intertwined with a person’s sense of identity. This integration into a person’s identity often makes the disorder highly resistant to conventional psychological interventions. Up to 30 percent of diagnosed individuals develop a chronic version of the illness that does not respond to standard care.
Because existing treatments often fail, scientists have started exploring alternative pharmacological approaches, including psychedelic substances. Psilocybin is a naturally occurring compound that interacts with serotonin receptors in the brain to produce altered states of consciousness. Recent systematic reviews of the literature by Francesco Bevione and colleagues highlighted that early, small-scale trials and case studies have provided evidence that psilocybin is generally safe for people with eating disorders.
Animal models have also provided insights into how this drug might operate in the brain. Research led by Claire J. Foldi demonstrated that psilocybin helped female rats subjected to an anorexia model maintain their body weight and improve their cognitive flexibility, which is the ability to adapt to new rules and environments.
This animal research indicated that the drug alters the expression of specific serotonin receptors in the brain, particularly the 5-HT1A and 5-HT2A receptors. However, related studies on mice suggest that psilocybin’s physiological effects, such as its impact on immune system inflammation, depend heavily on an animal’s physical state and environment.
To build on this preliminary data, a team of researchers from the Centre for Psychedelic Research at Imperial College London designed a pilot study to test the intervention in humans. The research was led by Hannah M. Douglass alongside Robin L. Carhart-Harris. They aimed to assess the safety, feasibility, and potential psychological benefits of psilocybin therapy in a group of adult women who had not responded to traditional anorexia treatments.
The researchers recruited 21 female participants between the ages of 23 and 52 who had a primary diagnosis of anorexia nervosa for at least three years. On average, the participants were 32 years old, had lived with the disorder for about 11 years, and had an average Body Mass Index (BMI) of 16.4. A healthy BMI is generally considered to be 18.5 or higher. The participants had not found long-term success with previous treatments.
The study utilized a single-blind, within-individual design, meaning there was no separate control group that received a placebo for the entire study. Over a six-week period, all 21 women attended three dosing sessions. They received a 1-milligram dose of psilocybin first, which was intended to be so low that it acted as a placebo. This was followed by two 25-milligram doses, spaced two weeks apart. Participants knew they were receiving psilocybin but did not know the dosage order.
Each dosing session took place in a supportive environment and was flanked by extensive preparation and integration talk therapy. Ten of the participants were required to withdraw from antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs), to prevent these drugs from blunting the psychedelic experience. The researchers monitored the participants’ safety, physical health, and psychological symptoms at multiple time points up to a year after the final session.
To measure eating disorder severity, the researchers primarily used the Eating Disorder Examination (EDE) interview, which involves a clinician assessing the patient’s symptoms. The participants had an average baseline EDE score of 3.2. The research team also used the Readiness and Motivation Questionnaire (RMQ) to track the participants’ self-reported motivation to recover.
The administration of psilocybin was well tolerated by the participants. All 21 women experienced at least one adverse event, but most were mild to moderate in severity. The most common side effects were transient headaches, reported by about 37 percent of participants, and nausea, reported by 25 percent. The study did not track BMI for the full year, but during the initial six weeks, the researchers noted no meaningful change in the participants’ body weight.
The clinician-administered assessments indicated that eating disorder symptoms decreased over time. The average global EDE score dropped by approximately 1.08 points by the final six-week visit. This reduction represents a massive relative drop from the 3.2 baseline score, yielding a large effect size. These improvements were generally sustained, with a 0.98-point reduction maintained at the six-month follow-up. Nearly all participants showed some level of improvement two weeks after the final session.
By the three-month mark, almost half of the participants had achieved symptom scores that fell within the range of a normal community population without an eating disorder. The researchers noted that individuals with a higher severity of symptoms at the start of the study tended to experience greater overall reductions in their scores. When analyzing the data, the scientists controlled for the potential impact of antidepressant withdrawal, finding that this variable did not alter the main outcomes.
The participants also self-reported changes in their mindset. The participants’ precontemplation scores on the RMQ decreased, indicating that their motivation to recover increased after the first 25-milligram dose. This shift toward wanting to change was sustained across the 12-month follow-up period. When comparing symptom reduction between the different dosage days, the differences were not statistically significant, indicating that the overall treatment package contributed to the psychological shifts rather than one specific dose.
Douglass, who led the study while completing her PhD at Imperial College London, reflected on the clinical outcomes. “This study delivered a brief program of psilocybin dosing and therapeutic support over a six-week period,” Douglass said. “Our results in individuals living with anorexia nervosa are encouraging, especially given that these participants had found previous treatments unsuccessful in maintaining their remission. However, further research is needed to assess how these findings might apply to a broader, more diverse population.”
The trial’s retention rate was 95.2 percent, with only one participant choosing to withdraw after the second dose due to the emotional and time commitments. Professor Robin Carhart-Harris, the senior author and trial designer, highlighted this particular success.
“This was a pioneering trial with promising results that justify larger and more rigorous studies,” Carhart-Harris said in a news release. “In particular, the retention rate was excellent, something that is often a real challenge in anorexia nervosa treatment. This was despite the considerable commitment required from participants involving day-long dosing sessions and several sessions of psychotherapy.”
The therapeutic context was an essential element of the intervention. Jennifer Danby, the lead therapist on the trial, noted how the psychedelic experience appeared to open new psychological doors for the patients.
“Having worked in the field of eating disorders for over 15 years it was encouraging to see that the trial, albeit with a very small cohort, provided an opportunity for individuals living with anorexia nervosa to approach treatment from a different angle,” Danby said. “Anorexia often serves as a protective mechanism for people and we saw participants be able to explore their relationship with the illness and gain some new perspectives. By laying fertile ground for change, even minor adjustments can lead to promising change longer term.”
David Erritzoe, another key researcher on the team, cautioned against treating the drug as a standalone cure. “The findings bear out further research, but it’s important to note that this was a particular dosing model carefully designed to support vulnerable participants with extensive psychological therapy alongside the psychedelic treatment,” Erritzoe said. “To be effective and safe, psychedelic treatments for individuals with complex mental health presentations, such as anorexia nervosa, should be given by trained clinicians in a supportive environment.”
The absence of a separate, drug-free control group makes it impossible to definitively attribute the observed psychological improvements to the psilocybin itself. Participants received roughly 50 hours of therapeutic contact during the six-week study. This intensive psychological support, combined with the natural passage of time, may have driven the reductions in eating disorder symptoms. A randomized controlled trial is necessary to separate the chemical effects of the drug from the benefits of the accompanying psychotherapy.
The study’s participants were relatively homogenous. The majority were highly educated white women. This demographic profile does not represent the full spectrum of individuals who suffer from eating disorders. The strict eligibility requirements also resulted in a sample of people who might have had more stable home environments or greater cognitive reserves, which can facilitate better therapeutic engagement. As a result, these findings cannot be readily generalized to a broader or more diverse population.
There was also a high degree of variation in how well the participants maintained their symptom improvements over the long term. Some individuals experienced a return of their eating disorder thoughts and behaviors during the one-year follow-up period. This variation indicates that psilocybin therapy might not induce permanent shifts for everyone and that post-study life events play a major role in long-term recovery.
During the follow-up period, one participant attempted suicide on two occasions. The study doctors and an independent safety board assessed these events and concluded they were unlikely to be related to the psilocybin intervention, given that they occurred seven and nine months after the final dosing session. These events highlight the elevated baseline risk of suicidality in populations with severe anorexia nervosa and the absolute necessity of rigorous clinical monitoring in psychiatric research.
The study, “Psilocybin therapy for adult females with anorexia nervosa: pilot study,” was authored by Hannah M. Douglass, Meg J. Spriggs, Kate Godfrey, Jennifer L. Danby, Frederico J. C. de Magalhaes, Lauren Macdonald, Kirsty L. Alderton, Stephanie Archer, Kirran Ahmad, Jonny Martell, Jennifer T. Frias, Gabriela Sawicka, Tim Read, Allan Blemings, Adele Lafrance, Dasha Nicholls, David Erritzoe, Rebecca J. Park, David J. Nutt, and Robin L. Carhart-Harris.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinForAnorexia #PsychedelicTherapy #EatingDisorderRecovery #AnorexiaNervosaTreatment #MentalHealthResearch #ImperialCollegePsychedelics # RMQ #EDEassessment #CompassionateCare #PsychotherapyPlusMedicine
-
DATE: July 18, 2026 at 06:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Brain scans reveal how LSD desynchronizes local neural activity to alter consciousness
A new analysis of brain imaging data reveals that lysergic acid diethylamide, commonly known as LSD, reduces the synchronization of local brain activity to produce its mind-altering effects. Published in the European Journal of Neuroscience, the research suggests the hallucinogenic drug interacts with a wider array of brain receptors than previously assumed. These insights help map the biological mechanisms underlying altered states of consciousness and could inform future therapeutic uses of psychedelics.
Over the past decade, medical researchers have renewed their focus on classic psychedelic drugs as potential treatments for psychiatric conditions. Compounds like LSD and psilocybin produce profound changes in perception, mood, and thought. Researchers largely attribute these effects to how the chemical binds to a specific type of serotonin receptor in the brain. But the drug structurally mimics several other chemical messengers, including dopamine and different subtypes of serotonin.
Paolo La-Torraca-Vittori, a researcher at the University of Pavia, and Livio Tarchi of the University of Florence led the current investigation. They aimed to fill a gap in current neuroimaging literature. Most brain scans of people on psychedelics look at large-scale, long-distance communication between widespread brain networks. Few studies have examined what happens to the tiny, localized clusters of brain cells when someone is under the influence of LSD.
The research team focused on two specific metrics that measure the resting state of the brain. The first metric captures the amplitude of low-frequency fluctuations. This assesses the power of slow, spontaneous brain waves in a very localized area. When a person is resting, their brain usually produces stable, low-frequency rhythms. A drop in this amplitude means the brain activity is becoming noisier, faster, and more desynchronized.
The second metric evaluates regional homogeneity. This assesses how well a tiny patch of brain tissue synchronizes its electrical activity with its immediate neighboring cells. High regional homogeneity indicates that a small cluster of neurons is firing together in unison. A drop in regional homogeneity suggests that local neurons are operating independently of one another.
To explain why this matters, scientists point to the entropic brain hypothesis. Entropy is a physics concept related to disorder and randomness. In neuroscience, higher entropy means a richer, less predictable pattern of brain states. The entropic brain hypothesis proposes that psychedelics push the brain into a state of higher entropy, increasing disorder in a way that allows for more flexible and dynamic thought processes.
The investigators utilized an open-access database containing the brain scans of 15 healthy adults. Because it involved fewer than 50 participants, this was a small study. During the original data collection, each participant underwent two brain scanning sessions held at least two weeks apart. On one day, they received an intravenous saline placebo. On the other day, they received a moderate, hallucinogenic dose of LSD.
The scanning took place roughly an hour after the drug was administered, capturing the peak of the psychedelic experience. The participants rested inside the scanner with their eyes closed. The scanning device tracked changes in blood flow to map neural activity. La-Torraca-Vittori, Tarchi, and their colleagues computed the two localized metrics for both the placebo and the LSD states. The researchers then overlaid these results onto established brain maps showing the typical distribution of various chemical receptors.
The analysis revealed widespread reductions in both the amplitude of low-frequency fluctuations and regional homogeneity when participants were under the influence of LSD. These drops were particularly pronounced in the visual and somatosensory cortices, the brain areas that process sight and incoming touch. The researchers noted that this local fragmentation forces the brain to abandon its normal hierarchical processing setup.
Normally, the human brain operates in a strict functional hierarchy. Sensory regions process basic inputs and then send that data up the chain to associative regions, which interpret the information. Under LSD, this structured hierarchy flattens. Instead of local clusters processing sensory information in specialized silos, the brain integrates information broadly across the entire cortex, blending visual and physical sensations.
The two metrics also highlighted distinct changes in other brain regions. The low-frequency fluctuation metric dropped heavily in areas associated with the default mode network. This network is a group of brain areas active during passive rest, daydreaming, and self-reflection. Disruptions in this network are strongly associated with the breakdown of the conscious self commonly reported by users of psychedelics.
At the same time, regional homogeneity decreased notably in deep subcortical regions like the thalamus and amygdala. These structures act as central hubs for sensory relay and emotional processing. When local synchronization drops in these relay centers, it likely changes how sensory information gets routed to the rest of the brain.
When linking these functional changes to brain chemistry, the team found robust correlations that expanded beyond the primary target of LSD. As expected, some localization related to the primary 5-HT2A serotonin receptor. Yet the drops in both brain metrics consistently mirrored the distribution patterns of dopamine D2 receptors and an alternative serotonin receptor known as 5-HT1A.
A receptor is a protein structure on the surface of a cell that receives chemical signals. When a chemical locks into a receptor, it triggers a biological response inside the cell. Brain areas with fewer of these specific dopamine and serotonin receptors experienced the greatest decreases in local synchronization and low-frequency rhythms under LSD.
This alignment dictates that LSD initiates a cascade of neurochemical events spanning multiple messenger systems. The authors suggest that regions enriched with certain dopamine and serotonin receptors might actually be shielded from the desynchronizing effects of the drug. Alternatively, the drug might indirectly activate these adjacent pathways, leading to the varied sensory and emotional shifts that characterize the experience.
While the data offers new perspectives on the physical mechanics of psychedelics, the researchers acknowledged several limitations. The analysis relied on a small sample size, requiring replication in broader populations to ensure the ultimate reliability of the findings. The team also used standardized maps of receptor density from a general population rather than maps of the actual participants’ brains, which limits the precision of the chemical correlations.
In addition, the resting scans analyzed in this project took place after a music-listening session. The researchers caution that the lingering emotional or neurological effects of listening to music could have shaped the resting state data independently of the chemical infusion. A slight difference in head motion between the placebo and LSD groups remained even after data filtering, leaving open the possibility of minor scanning artifacts.
Future investigations will likely compare these localized measures with other brain monitoring technologies. By mapping both the physical location and the precise timing of these neural changes, scientists hope to fully decode how altered brain chemistry reshapes the human mind. The exploration of localized dynamics offers a key stepping stone toward developing safe, targeted psychedelic therapies in the future.
The study, “Knocking at the Doors of Perception: Relating LSD Effects on Low-Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI,” was authored by Paolo La-Torraca-Vittori, Livio Tarchi, Elisa Arrigo, Stefano Lanterna, Eleonora Tosi, Arne Doose, Fulvia Palesi, Doris Pischedda, Valdo Ricca, Paolo Fusar-Poli, and Stefano Damiani.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LSD BrainImaging #PsychedelicResearch #Neuroscience #BrainConnectivity #LowFrequencyFluctuations #RegionalHomogeneity #5HT2A #DopamineD2 #ConsciousnessAlteration #PsychedelicTherapy
-
DATE: July 18, 2026 at 06:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Brain scans reveal how LSD desynchronizes local neural activity to alter consciousness
A new analysis of brain imaging data reveals that lysergic acid diethylamide, commonly known as LSD, reduces the synchronization of local brain activity to produce its mind-altering effects. Published in the European Journal of Neuroscience, the research suggests the hallucinogenic drug interacts with a wider array of brain receptors than previously assumed. These insights help map the biological mechanisms underlying altered states of consciousness and could inform future therapeutic uses of psychedelics.
Over the past decade, medical researchers have renewed their focus on classic psychedelic drugs as potential treatments for psychiatric conditions. Compounds like LSD and psilocybin produce profound changes in perception, mood, and thought. Researchers largely attribute these effects to how the chemical binds to a specific type of serotonin receptor in the brain. But the drug structurally mimics several other chemical messengers, including dopamine and different subtypes of serotonin.
Paolo La-Torraca-Vittori, a researcher at the University of Pavia, and Livio Tarchi of the University of Florence led the current investigation. They aimed to fill a gap in current neuroimaging literature. Most brain scans of people on psychedelics look at large-scale, long-distance communication between widespread brain networks. Few studies have examined what happens to the tiny, localized clusters of brain cells when someone is under the influence of LSD.
The research team focused on two specific metrics that measure the resting state of the brain. The first metric captures the amplitude of low-frequency fluctuations. This assesses the power of slow, spontaneous brain waves in a very localized area. When a person is resting, their brain usually produces stable, low-frequency rhythms. A drop in this amplitude means the brain activity is becoming noisier, faster, and more desynchronized.
The second metric evaluates regional homogeneity. This assesses how well a tiny patch of brain tissue synchronizes its electrical activity with its immediate neighboring cells. High regional homogeneity indicates that a small cluster of neurons is firing together in unison. A drop in regional homogeneity suggests that local neurons are operating independently of one another.
To explain why this matters, scientists point to the entropic brain hypothesis. Entropy is a physics concept related to disorder and randomness. In neuroscience, higher entropy means a richer, less predictable pattern of brain states. The entropic brain hypothesis proposes that psychedelics push the brain into a state of higher entropy, increasing disorder in a way that allows for more flexible and dynamic thought processes.
The investigators utilized an open-access database containing the brain scans of 15 healthy adults. Because it involved fewer than 50 participants, this was a small study. During the original data collection, each participant underwent two brain scanning sessions held at least two weeks apart. On one day, they received an intravenous saline placebo. On the other day, they received a moderate, hallucinogenic dose of LSD.
The scanning took place roughly an hour after the drug was administered, capturing the peak of the psychedelic experience. The participants rested inside the scanner with their eyes closed. The scanning device tracked changes in blood flow to map neural activity. La-Torraca-Vittori, Tarchi, and their colleagues computed the two localized metrics for both the placebo and the LSD states. The researchers then overlaid these results onto established brain maps showing the typical distribution of various chemical receptors.
The analysis revealed widespread reductions in both the amplitude of low-frequency fluctuations and regional homogeneity when participants were under the influence of LSD. These drops were particularly pronounced in the visual and somatosensory cortices, the brain areas that process sight and incoming touch. The researchers noted that this local fragmentation forces the brain to abandon its normal hierarchical processing setup.
Normally, the human brain operates in a strict functional hierarchy. Sensory regions process basic inputs and then send that data up the chain to associative regions, which interpret the information. Under LSD, this structured hierarchy flattens. Instead of local clusters processing sensory information in specialized silos, the brain integrates information broadly across the entire cortex, blending visual and physical sensations.
The two metrics also highlighted distinct changes in other brain regions. The low-frequency fluctuation metric dropped heavily in areas associated with the default mode network. This network is a group of brain areas active during passive rest, daydreaming, and self-reflection. Disruptions in this network are strongly associated with the breakdown of the conscious self commonly reported by users of psychedelics.
At the same time, regional homogeneity decreased notably in deep subcortical regions like the thalamus and amygdala. These structures act as central hubs for sensory relay and emotional processing. When local synchronization drops in these relay centers, it likely changes how sensory information gets routed to the rest of the brain.
When linking these functional changes to brain chemistry, the team found robust correlations that expanded beyond the primary target of LSD. As expected, some localization related to the primary 5-HT2A serotonin receptor. Yet the drops in both brain metrics consistently mirrored the distribution patterns of dopamine D2 receptors and an alternative serotonin receptor known as 5-HT1A.
A receptor is a protein structure on the surface of a cell that receives chemical signals. When a chemical locks into a receptor, it triggers a biological response inside the cell. Brain areas with fewer of these specific dopamine and serotonin receptors experienced the greatest decreases in local synchronization and low-frequency rhythms under LSD.
This alignment dictates that LSD initiates a cascade of neurochemical events spanning multiple messenger systems. The authors suggest that regions enriched with certain dopamine and serotonin receptors might actually be shielded from the desynchronizing effects of the drug. Alternatively, the drug might indirectly activate these adjacent pathways, leading to the varied sensory and emotional shifts that characterize the experience.
While the data offers new perspectives on the physical mechanics of psychedelics, the researchers acknowledged several limitations. The analysis relied on a small sample size, requiring replication in broader populations to ensure the ultimate reliability of the findings. The team also used standardized maps of receptor density from a general population rather than maps of the actual participants’ brains, which limits the precision of the chemical correlations.
In addition, the resting scans analyzed in this project took place after a music-listening session. The researchers caution that the lingering emotional or neurological effects of listening to music could have shaped the resting state data independently of the chemical infusion. A slight difference in head motion between the placebo and LSD groups remained even after data filtering, leaving open the possibility of minor scanning artifacts.
Future investigations will likely compare these localized measures with other brain monitoring technologies. By mapping both the physical location and the precise timing of these neural changes, scientists hope to fully decode how altered brain chemistry reshapes the human mind. The exploration of localized dynamics offers a key stepping stone toward developing safe, targeted psychedelic therapies in the future.
The study, “Knocking at the Doors of Perception: Relating LSD Effects on Low-Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI,” was authored by Paolo La-Torraca-Vittori, Livio Tarchi, Elisa Arrigo, Stefano Lanterna, Eleonora Tosi, Arne Doose, Fulvia Palesi, Doris Pischedda, Valdo Ricca, Paolo Fusar-Poli, and Stefano Damiani.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #LSD BrainImaging #PsychedelicResearch #Neuroscience #BrainConnectivity #LowFrequencyFluctuations #RegionalHomogeneity #5HT2A #DopamineD2 #ConsciousnessAlteration #PsychedelicTherapy
-
Psychedelics: A Rush Towards Regulatory Acceptance
Government is making it faster to approve new psychedelic drugs for depression, PTSD, and addiction. Find out how this helps patients.
#PsychedelicTherapy, #MentalHealth, #DrugApproval, #FDA, #NewTreatments
https://newsletter.tf/psychedelic-drug-rules-speed-approval-mental-health/
-
Psychedelics: A Rush Towards Regulatory Acceptance
Government is making it faster to approve new psychedelic drugs for depression, PTSD, and addiction. Find out how this helps patients.
#PsychedelicTherapy, #MentalHealth, #DrugApproval, #FDA, #NewTreatments
https://newsletter.tf/psychedelic-drug-rules-speed-approval-mental-health/
-
New rules mean psychedelic drugs for mental health could reach patients years sooner than expected. This is a big change from old rules.
#PsychedelicTherapy, #MentalHealth, #DrugApproval, #FDA, #NewTreatments
https://newsletter.tf/psychedelic-drug-rules-speed-approval-mental-health/ -
New rules mean psychedelic drugs for mental health could reach patients years sooner than expected. This is a big change from old rules.
#PsychedelicTherapy, #MentalHealth, #DrugApproval, #FDA, #NewTreatments
https://newsletter.tf/psychedelic-drug-rules-speed-approval-mental-health/ -
#Psilocybin #MentalHealth #DepressionTreatment #PsychedelicTherapy #PsychiatricCare #MushroomMedicine #WellnessJourney #NewHope #wellnessgoals #wellnessadvocate #wellnesscoaching #wellnessfitness #wellnesscenter #wellnesscommunity #TherapeuticPsychedelics #Mindfulness https://mastodon.social/@biohackingpathway/116588891740098770
-
#Psilocybin #MentalHealth #DepressionTreatment #PsychedelicTherapy #PsychiatricCare #MushroomMedicine #WellnessJourney #NewHope #wellnessgoals #wellnessadvocate #wellnesscoaching #wellnessfitness #wellnesscenter #wellnesscommunity #TherapeuticPsychedelics #Mindfulness https://mastodon.social/@biohackingpathway/116588891740098770
-
G.O.P. Optics Shift: Psychedelics Emerge from Shadows, Courted by the Unlikely
Republicans are changing their view on psychedelics like psilocybin. Once seen as fringe, they are now considered for mental health treatment.
#PsychedelicTherapy, #GOP, #MentalHealth, #Psilocybin, #DrugPolicy
https://newsletter.tf/gop-psychedelics-therapy-shift-republicans/
-
G.O.P. Optics Shift: Psychedelics Emerge from Shadows, Courted by the Unlikely
Republicans are changing their view on psychedelics like psilocybin. Once seen as fringe, they are now considered for mental health treatment.
#PsychedelicTherapy, #GOP, #MentalHealth, #Psilocybin, #DrugPolicy
https://newsletter.tf/gop-psychedelics-therapy-shift-republicans/
-
Psychedelic drugs like psilocybin are moving from the counterculture to mainstream medical research, with some political groups now considering their use.
#PsychedelicTherapy, #GOP, #MentalHealth, #Psilocybin, #DrugPolicy
https://newsletter.tf/gop-psychedelics-therapy-shift-republicans/ -
Psychedelic drugs like psilocybin are moving from the counterculture to mainstream medical research, with some political groups now considering their use.
#PsychedelicTherapy, #GOP, #MentalHealth, #Psilocybin, #DrugPolicy
https://newsletter.tf/gop-psychedelics-therapy-shift-republicans/ -
For what is is the point is to get help to those that would need it. That is what matters about life changes about your future being able to fix it in the point of Psychedelic Therapy! See the shaman your therapist! #psychedelictherapy https://walmartramen.blogspot.com/2026/04/its-more-about-culture-is-your.html
-
Is it depression or Autistic Burnout?
For years, I lived under the wrong diagnosis. Traditional treatments fail when we mistake a nervous system paralyzed by "masking" for a simple chemical imbalance.
In my latest article, I explore the neurobiology of burnout and the emerging role of psilocybin as a "window of plasticity" for the autistic brain.
Read the full piece here:
https://medium.com/the-unexpected-autistic-life/is-it-depression-or-autistic-burnout-why-the-difference-matters-for-psychedelic-therapy-589f0e108c91
#Neurodiversity #AutisticBurnout #MentalHealth #PsychedelicTherapy #Psilocybin #ActuallyAutistic -
Is it depression or Autistic Burnout?
For years, I lived under the wrong diagnosis. Traditional treatments fail when we mistake a nervous system paralyzed by "masking" for a simple chemical imbalance.
In my latest article, I explore the neurobiology of burnout and the emerging role of psilocybin as a "window of plasticity" for the autistic brain.
Read the full piece here:
https://medium.com/the-unexpected-autistic-life/is-it-depression-or-autistic-burnout-why-the-difference-matters-for-psychedelic-therapy-589f0e108c91
#Neurodiversity #AutisticBurnout #MentalHealth #PsychedelicTherapy #Psilocybin #ActuallyAutistic